litlas
Log inCreate account

Gary L. Davis

Active 1983–2022

Also published as
GARY L. DAVIS
78
Papers
19,019
Citations
75
h-index
78
i10-index

Citations

Citations per year for Gary L. Davis1974: 1 citations1985: 13 citations1986: 4 citations1987: 27 citations1988: 20 citations1989: 39 citations1990: 41 citations1991: 68 citations1992: 73 citations1993: 93 citations1994: 91 citations1995: 117 citations1996: 100 citations1997: 124 citations1998: 130 citations1999: 155 citations2000: 182 citations2001: 178 citations2002: 165 citations2003: 136 citations2004: 153 citations2005: 124 citations2006: 148 citations2007: 125 citations2008: 120 citations2009: 106 citations2010: 95 citations2011: 110 citations2012: 117 citations2013: 119 citations2014: 110 citations2015: 121 citations2016: 76 citations2017: 55 citations2018: 65 citations2019: 157 citations2020: 144 citations2021: 110 citations2022: 74 citations2023: 38 citations2024: 77 citations2025: 25 citations1975–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,786 citing papers, 35.8% of this breakdownUnited Kingdom: 353 citing papers, 7.1% of this breakdownFrance: 313 citing papers, 6.3% of this breakdownGermany: 268 citing papers, 5.4% of this breakdownItaly: 248 citing papers, 5% of this breakdownJapan: 228 citing papers, 4.6% of this breakdownChina: 187 citing papers, 3.8% of this breakdownCanada: 165 citing papers, 3.3% of this breakdownSpain: 165 citing papers, 3.3% of this breakdownAustralia: 131 citing papers, 2.6% of this breakdownSwitzerland: 95 citing papers, 1.9% of this breakdownNetherlands: 80 citing papers, 1.6% of this breakdown
0%35.8%Other 19.3%

Institutions

Fields

  • Medicine83.4%
  • Biochemistry, Genetics and Molecular Biology7.8%
  • Immunology and Microbiology4%
  • Neuroscience1.5%
  • Agricultural and Biological Sciences0.8%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2%

Topics

  • Hepatitis C virus research14.6%
  • Liver Disease Diagnosis and Treatment11.2%
  • Hepatitis B Virus Studies8.5%
  • Liver Disease and Transplantation4.4%
  • Hepatocellular Carcinoma Treatment and Prognosis2.9%
  • Liver Diseases and Immunity2.6%
  • Other55.8%

Coauthors

All papers

Open in search
  1. A selective small-molecule inhibitor of macrophage migration inhibitory factor-2 (MIF-2), a MIF cytokine superfamily member, inhibits MIF-2 biological activity

    Authors: Pathricia V. Tilstam, Georgios Pantouris, Michael L. Corman, Monica Andreoli, Keyvan Mahboubi, Gary L. Davis, Xin Du, Lin Leng, Elias Lolis, Richard Bucala - Journal of Biological Chemistry 2019 cited by 42

  2. European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018–2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)

    Authors: Virginie Viprey, Guido Granata, Karuna E.W. Vendrik, Gary L. Davis, Nicola Petrosillo, Ed J. Kuijper, Tuba Vilken, Christine Lammens, Joost Schotsman, Angela D. Benson, Maria Adriana Cataldo, Tjallie van der Kooi, Mark H. Wilcox, Kerrie Davies - Journal of Hospital Infection 2022 cited by 34

  3. Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-Regulation of Hexokinase 2 and Poor Prognosis

    Authors: Diane Palmieri, Daniel P. Fitzgerald, S. Martin Shreeve, Emily Hua, Julie L. Bronder, Robert J. Weil, Sean Davis, Andreas M. Stark, Maria J. Merino, Raffael Kurek, H. Maximilian Mehdorn, Gary L. Davis, Seth M. Steinberg, Paul S. Meltzer, Kenneth Aldape, Patricia S. Steeg - Molecular Cancer Research 2009 cited by 213

  4. The major human rhinovirus receptor is ICAM-1

    Authors: Jeffrey M. Greve, Gary L. Davis, Ann Meyer, Carla Forte, Susan Yost, Christopher W. Marlor, Michael E. Kamarck, Alan McClelland - Cell 1989 cited by 1,151

  5. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression

    Authors: Gary L. Davis, Miriam J. Alter, Hashem B. El‐Serag, Thierry Poynard, Linda W. Jennings - Gastroenterology 2009 cited by 882

  6. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease

    Authors: Kanthi Yalamanchili, Sherif Saadeh, Göran B. Klintmalm, Linda W. Jennings, Gary L. Davis - Liver Transplantation 2009 cited by 228

  7. Indications for Liver Transplantation

    Authors: Jacqueline G. O’Leary, Rita Lepe, Gary L. Davis - Gastroenterology 2008 cited by 213

  8. Orbital Invasion by Periocular Basal Cell Carcinoma

    Authors: Igal Leibovitch, Alan A. McNab, Timothy J. Sullivan, Gary L. Davis, Dinesh Selva - Ophthalmology 2005 cited by 177

  9. Impact of Sirolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation

    Authors: Srinath Chinnakotla, Gary L. Davis, Sugam Vasani, Peter Kim, Koji Tomiyama, Edmund Q. Sanchez, Nicholas Onaca, Robert M. Goldstein, Marlon F. Levy, Göran B. Klintmalm - Liver Transplantation 2009 cited by 151

  10. Improved Results of Transplantation for Hepatocellular Carcinoma: A Report From the International Registry of Hepatic Tumors in Liver Transplantation

    Authors: Nicholas Onaca, Gary L. Davis, Linda W. Jennings, Robert M. Goldstein, Göran B. Klintmalm - Liver Transplantation 2009 cited by 75

  11. Expanded Criteria for Liver Transplantation in Patients with Hepatocellular Carcinoma

    Authors: Nicholas Onaca, Gary L. Davis, Robert M. Goldstein, Linda W. Jennings, Göran B. Klintmalm - Liver Transplantation 2007 cited by 188

  12. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse

    Authors: Mustafa Al’Absi, Dorothy Hatsukami, Gary L. Davis - Psychopharmacology 2005 cited by 188

  13. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation

    Authors: John K. O’Connor, James F. Trotter, Gary L. Davis, Jane Dempster, Göran B. Klintmalm, Robert M. Goldstein - Liver Transplantation 2012 cited by 168

  14. High Mean Fluorescence Intensity Donor-Specific Anti-HLA Antibodies Associated With Chronic Rejection Postliver Transplant

    Authors: Jacqueline G. O’Leary, Hugo Kaneku, B. Süßkind, Linda W. Jennings, Michael A. Neri, Gary L. Davis, Göran B. Klintmalm, Paul I. Terasaki - American Journal of Transplantation 2011 cited by 167

  15. A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

    Authors: Robert P. Perrillo, Eugene R. Schiff, Gary L. Davis, Henry C. Bodenheimer, Karen L. Lindsay, John A. Payne, Jules L. Dienstag, Christopher O'Brien, Carlo H. Tamburro, Ira M. Jacobson, Richard E. Sampliner, David Feit, Jay H. Lefkowitch, Mary C. Kuhns, Carlton Meschievitz, Bharati Sanghvi, Janice K. Albrecht, Alexandra L. Gibas - New England Journal of Medicine 1990 cited by 850

  16. Hepatocellular Carcinoma: Management of an Increasingly Common Problem

    Authors: Gary L. Davis, Jane Dempster, James D. Meler, Douglas Orr, Mark W. Walberg, Brian D. Brown, Brian D. Berger, John K. O’Connor, Robert M. Goldstein - Baylor University Medical Center Proceedings 2008 cited by 205

  17. Activation of Tumor Necrosis Factor-α System in Chronic Hepatitis C Virus Infection

    Authors: David R. Nelson, Herbert L. Lim, Constantine G. Marousis, Jane Fang, Gary L. Davis, Luping Shen, Mickey S. Urdea, Janice A. Kolberg, Johnson Y.N. Lau - Digestive Diseases and Sciences 1997 cited by 205

  18. The Impact of Treatment of Portopulmonary Hypertension on Survival Following Liver Transplantation

    Authors: Muhammad Ashfaq, S. Chinnakotla, Lindsay S. Rogers, K. Ausloos, Salwa Saadeh, Göran B. Klintmalm, Michael A. E. Ramsay, Gary L. Davis - American Journal of Transplantation 2007 cited by 187

  19. Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula

    Authors: Richard B. Freeman, Robert G. Gish, Ann Harper, Gary L. Davis, John M. Vierling, Leslie Lieblein, Göran B. Klintmalm, Jamie Blazek, R.A. Hunter, Jeffrey D. Punch - Liver Transplantation 2006 cited by 175

  20. Long–Term Interleukin 10 Therapy in Chronic Hepatitis C Patients Has A Proviral and Anti–Inflammatory Effect

    Authors: David R. Nelson, Zhengkun Tu, Consuelo Soldevila‐Pico, Manal F. Abdelmalek, Haizhen Zhu, Yi Xu, Roniel Cabrera, Chen Liu, Gary L. Davis - Hepatology 2003 cited by 122

  21. Ascitic Fluid Lactoferrin for Diagnosis of Spontaneous Bacterial Peritonitis

    Authors: Mansour A. Parsi, Sherif Saadeh, Nizar N. Zein, Gary L. Davis, Rocío López, James H. Boone, Maria R. Lepe, Linsheng Guo, Mohammad Ashfaq, Göran Klintmalm, Arthur J. McCullough - Gastroenterology 2008 cited by 91

  22. Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

    Authors: Gary L. Davis, Luis A. Balart, Eugene R. Schiff, Karen L. Lindsay, Henry C. Bodenheimer, Robert P. Perrillo, William Carey, Ira M. Jacobson, John A. Payne, Jules L. Dienstag, David VanThiel, Carlo H. Tamburro, Jay H. Lefkowitch, Janice K. Albrecht, Carlton Meschievitz, Terryl J. Ortego, Alexandra L. Gibas, The Hepatitis Interventional Therapy Group - New England Journal of Medicine 1989 cited by 1,651

  23. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

    Authors: Gary L. Davis, Rafael Esteban, Vinod K. Rustgi, John C. Hoefs, Stuart C. Gordon, Christian Trépo, Mitchell L. Shiffman, Stefan Zeuzem, Antonio Craxı̀, Mei-Hsiu Ling, Janice K. Albrecht - New England Journal of Medicine 1998 cited by 1,300

  24. Projecting future complications of chronic hepatitis C in the United States

    Authors: Gary L. Davis, James E. Albright, Suzanne F. Cook, Daniel M. Rosenberg - Liver Transplantation 2003 cited by 579